Immunorad
@immunorad.bsky.social
We're delighted to announce that the 10th edition of the Immunorad conference will take place in New York City, September 23-25 2026!
📰 #UpdateYourRefs !
⚡ New breakthrough study revealing that a unique #proteotoxic #stress response (Tex-PSR) is a key mechanistic driver of T cell #exhaustion and #immune evasion in cancer. Targeting this proteostasis pathway represents a promising new approach for enhancing cancer #immunotherapy.
⚡ New breakthrough study revealing that a unique #proteotoxic #stress response (Tex-PSR) is a key mechanistic driver of T cell #exhaustion and #immune evasion in cancer. Targeting this proteostasis pathway represents a promising new approach for enhancing cancer #immunotherapy.
October 6, 2025 at 12:37 AM
📰 #UpdateYourRefs !
⚡ New breakthrough study revealing that a unique #proteotoxic #stress response (Tex-PSR) is a key mechanistic driver of T cell #exhaustion and #immune evasion in cancer. Targeting this proteostasis pathway represents a promising new approach for enhancing cancer #immunotherapy.
⚡ New breakthrough study revealing that a unique #proteotoxic #stress response (Tex-PSR) is a key mechanistic driver of T cell #exhaustion and #immune evasion in cancer. Targeting this proteostasis pathway represents a promising new approach for enhancing cancer #immunotherapy.
“Nuclear medicine at the era of AI and precision medicine” from Désirée Deandreis (Gustave Roussy).
Key insights in the LinkedIn post ➡️ www.linkedin.com/feed/update/...
Key insights in the LinkedIn post ➡️ www.linkedin.com/feed/update/...
September 19, 2025 at 3:43 PM
“Nuclear medicine at the era of AI and precision medicine” from Désirée Deandreis (Gustave Roussy).
Key insights in the LinkedIn post ➡️ www.linkedin.com/feed/update/...
Key insights in the LinkedIn post ➡️ www.linkedin.com/feed/update/...
“Biomarker-guided selection for FLASH and low-dose immunomodulation” from Dr Fernanda Herrera (CHUV Lausanne University Hospital).
Key insights on the LinkedIn post ➡️ www.linkedin.com/feed/update/...
Key insights on the LinkedIn post ➡️ www.linkedin.com/feed/update/...
✨ Biomarker-guided selection for FLASH and low-dose immunomodulation (LDRT)
Dr. Fernanda Herrera shared new insights on how low-dose radiotherapy (LDRT) and FLASH RT may reshape immunotherapy… | Immun...
✨ Biomarker-guided selection for FLASH and low-dose immunomodulation (LDRT)
Dr. Fernanda Herrera shared new insights on how low-dose radiotherapy (LDRT) and FLASH RT may reshape immunotherapy strategi...
www.linkedin.com
September 19, 2025 at 2:09 PM
“Biomarker-guided selection for FLASH and low-dose immunomodulation” from Dr Fernanda Herrera (CHUV Lausanne University Hospital).
Key insights on the LinkedIn post ➡️ www.linkedin.com/feed/update/...
Key insights on the LinkedIn post ➡️ www.linkedin.com/feed/update/...
⏱️ Live Feed: Pr Laurence Zitvogel (Gustave Roussy, France) talked about the #metabolism at the cross road between gut #commensalism and
cancer #immunosurveillance.
cancer #immunosurveillance.
September 19, 2025 at 1:51 PM
⏱️ Live Feed: Pr Laurence Zitvogel (Gustave Roussy, France) talked about the #metabolism at the cross road between gut #commensalism and
cancer #immunosurveillance.
cancer #immunosurveillance.
"Interventional radiology for cancer immunotherapy: past, present, and future” from Pr Lambros Tselikas (Gustave Roussy).
Key insights on the LinkedIn post ➡️ www.linkedin.com/feed/update/...
Key insights on the LinkedIn post ➡️ www.linkedin.com/feed/update/...
September 19, 2025 at 10:36 AM
"Interventional radiology for cancer immunotherapy: past, present, and future” from Pr Lambros Tselikas (Gustave Roussy).
Key insights on the LinkedIn post ➡️ www.linkedin.com/feed/update/...
Key insights on the LinkedIn post ➡️ www.linkedin.com/feed/update/...
⏱️ Live Feed: Pr eric deutsch (Gustave Roussy, France) talked about translational frontiers and clinical opportunities of #immunologically fitted #radiotherapy.
September 19, 2025 at 9:55 AM
⏱️ Live Feed: Pr eric deutsch (Gustave Roussy, France) talked about translational frontiers and clinical opportunities of #immunologically fitted #radiotherapy.
“The use of PET for assessing on-treatment changes in radiolabeled anti-PD-L1 uptake during chemoradiotherapy in NSCLC” from Pr Idris Bahce.
Key insights on LinkedIn ➡️ www.linkedin.com/feed/update/...
Key insights on LinkedIn ➡️ www.linkedin.com/feed/update/...
September 19, 2025 at 9:33 AM
“The use of PET for assessing on-treatment changes in radiolabeled anti-PD-L1 uptake during chemoradiotherapy in NSCLC” from Pr Idris Bahce.
Key insights on LinkedIn ➡️ www.linkedin.com/feed/update/...
Key insights on LinkedIn ➡️ www.linkedin.com/feed/update/...
"“Tumor immune microenvironment delineates the evolutionary trajectories of distinct phenotypes of locoregionally-advanced EBV-positive nasopharyngeal carcinoma” from Pr Melvin LK Chua (National Cancer Center Singapore).
Key insights on LinkedIn➡️ www.linkedin.com/feed/update/...
Key insights on LinkedIn➡️ www.linkedin.com/feed/update/...
🌐 Tumor immune microenvironment as a guide in EBV⁺ nasopharyngeal carcinoma
To close the Tumor Microenvironment session at ImmunoRad 2025, Prof. Melvin L.K. Chua (Singapore) explored how the tumor… | ...
🌐 Tumor immune microenvironment as a guide in EBV⁺ nasopharyngeal carcinoma
To close the Tumor Microenvironment session at ImmunoRad 2025, Prof. Melvin L.K. Chua (Singapore) explored how the tumor imm...
www.linkedin.com
September 19, 2025 at 8:20 AM
"“Tumor immune microenvironment delineates the evolutionary trajectories of distinct phenotypes of locoregionally-advanced EBV-positive nasopharyngeal carcinoma” from Pr Melvin LK Chua (National Cancer Center Singapore).
Key insights on LinkedIn➡️ www.linkedin.com/feed/update/...
Key insights on LinkedIn➡️ www.linkedin.com/feed/update/...
⏱️ Live Feed: Dr. Maria E. Rodriguez Ruiz (University of Navarra, Spain) talked about the exploitation of #FAP-inducibility and cross-priming requirements in #radioimmunotherapy.
September 19, 2025 at 7:38 AM
⏱️ Live Feed: Dr. Maria E. Rodriguez Ruiz (University of Navarra, Spain) talked about the exploitation of #FAP-inducibility and cross-priming requirements in #radioimmunotherapy.
"NNMT inhibition in cancer-associated fibroblasts restores antitumor immunity" from Dr Janna Heide.
Key insights in the LinkedIn post➡️ www.linkedin.com/feed/update/...
Key insights in the LinkedIn post➡️ www.linkedin.com/feed/update/...
September 18, 2025 at 4:44 PM
"NNMT inhibition in cancer-associated fibroblasts restores antitumor immunity" from Dr Janna Heide.
Key insights in the LinkedIn post➡️ www.linkedin.com/feed/update/...
Key insights in the LinkedIn post➡️ www.linkedin.com/feed/update/...
⏱️ Live Feed: Pr Ignacio Melero (Clínica Universidad de Navarra, Spain) talked about low dose and #neutrophil extracellular traps (#NETs).
September 18, 2025 at 4:22 PM
⏱️ Live Feed: Pr Ignacio Melero (Clínica Universidad de Navarra, Spain) talked about low dose and #neutrophil extracellular traps (#NETs).
“Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma” from Jérôme Galon (Cordeliers Research Center) during the "Next Generation Immunotherapy" session.
Key insights on LinkedIn ➡️ www.linkedin.com/feed/update/...
Key insights on LinkedIn ➡️ www.linkedin.com/feed/update/...
September 18, 2025 at 3:37 PM
“Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma” from Jérôme Galon (Cordeliers Research Center) during the "Next Generation Immunotherapy" session.
Key insights on LinkedIn ➡️ www.linkedin.com/feed/update/...
Key insights on LinkedIn ➡️ www.linkedin.com/feed/update/...
⏱️ Live Feed: Pr Kevin Harrington (ICR, UK) presented a comprehensive talk about #STING agonism during adjuvant #immunotherapy for #radiocurable cancers.
September 18, 2025 at 1:48 PM
⏱️ Live Feed: Pr Kevin Harrington (ICR, UK) presented a comprehensive talk about #STING agonism during adjuvant #immunotherapy for #radiocurable cancers.
Second talk of the “DNA Damage” session: “Epigenetic, Transcriptomic and genetic analyses of HR+/HER2- primary and metastatic breast cancer reveals heterogeneous mechanisms of endocrine therapy resistance” from Dr Sergey Nikolaev (Gustave Roussy).
Key insights ➡️ www.linkedin.com/feed/update/...
Key insights ➡️ www.linkedin.com/feed/update/...
🧬 Unraveling endocrine therapy resistance in HR⁺/HER2⁻ breast cancer
In the DNA Damage session, Dr. Sergey Nikolaev (Gustave Roussy) presented multi-omic insights into why HR⁺/HER2⁻ breast cancers… | ...
🧬 Unraveling endocrine therapy resistance in HR⁺/HER2⁻ breast cancer
In the DNA Damage session, Dr. Sergey Nikolaev (Gustave Roussy) presented multi-omic insights into why HR⁺/HER2⁻ breast cancers dev...
www.linkedin.com
September 18, 2025 at 1:24 PM
Second talk of the “DNA Damage” session: “Epigenetic, Transcriptomic and genetic analyses of HR+/HER2- primary and metastatic breast cancer reveals heterogeneous mechanisms of endocrine therapy resistance” from Dr Sergey Nikolaev (Gustave Roussy).
Key insights ➡️ www.linkedin.com/feed/update/...
Key insights ➡️ www.linkedin.com/feed/update/...
Last talk of the “Immunosuppression” session at Immunorad 2025: “Microbiota-primed fibroblasts contribute to radiotherapy-induced lung metastasis progression” by Dr Andras Piffko from University Medical Center (Hamburg-Eppendorf). Key highlights on the LinkedIn post➡️ www.linkedin.com/feed/update/...
September 18, 2025 at 10:47 AM
Last talk of the “Immunosuppression” session at Immunorad 2025: “Microbiota-primed fibroblasts contribute to radiotherapy-induced lung metastasis progression” by Dr Andras Piffko from University Medical Center (Hamburg-Eppendorf). Key highlights on the LinkedIn post➡️ www.linkedin.com/feed/update/...
⏱️ Live Feed: Dr. Monica Olcina (University of Oxford, UK) discussed how targeting the #complement receptor #C5aR1 could enhance #radiotherapy efficacy in #immunosuppressive tumor #microenvironments.
September 18, 2025 at 10:16 AM
⏱️ Live Feed: Dr. Monica Olcina (University of Oxford, UK) discussed how targeting the #complement receptor #C5aR1 could enhance #radiotherapy efficacy in #immunosuppressive tumor #microenvironments.
"Unraveling the complexity of cancer ecosystems following therapeutic intervention" from Pr Johanna Joyce in the "Immunosuppression" session.
Highlights of the talk on Linkedin➡️ www.linkedin.com/feed/update/...
Highlights of the talk on Linkedin➡️ www.linkedin.com/feed/update/...
September 18, 2025 at 9:19 AM
"Unraveling the complexity of cancer ecosystems following therapeutic intervention" from Pr Johanna Joyce in the "Immunosuppression" session.
Highlights of the talk on Linkedin➡️ www.linkedin.com/feed/update/...
Highlights of the talk on Linkedin➡️ www.linkedin.com/feed/update/...
⏱️ Live Feed: Dr. Yungan TAO (Gustave Roussy, France) delivered a comprehensive update on the evolving role of #immunotherapy combined with hashtag#radiotherapy in head and neck squamous cell carcinoma (#HNSCC).
September 18, 2025 at 8:08 AM
⏱️ Live Feed: Dr. Yungan TAO (Gustave Roussy, France) delivered a comprehensive update on the evolving role of #immunotherapy combined with hashtag#radiotherapy in head and neck squamous cell carcinoma (#HNSCC).
⏱️ Live Feed: Great presentation from Anne-Gaëlle Goubet (University of Geneva, Switzerland)
September 18, 2025 at 7:23 AM
⏱️ Live Feed: Great presentation from Anne-Gaëlle Goubet (University of Geneva, Switzerland)
"Heterogeneous intratumor irradiation: a new partner for immunotherapy" from Dr. Michele Mondini. Key insights from the talk on LinkedIn ➡️ www.linkedin.com/feed/update/...
During the second talk of the “Radiation dose, modalities and resistance” session, Dr. Michele Mondini presented exciting preclinical insights into SFRT — moving beyond the traditional dogma of… | Imm...
During the second talk of the “Radiation dose, modalities and resistance” session, Dr. Michele Mondini presented exciting preclinical insights into SFRT — moving beyond the traditional dogma of unifor...
www.linkedin.com
September 17, 2025 at 4:08 PM
"Heterogeneous intratumor irradiation: a new partner for immunotherapy" from Dr. Michele Mondini. Key insights from the talk on LinkedIn ➡️ www.linkedin.com/feed/update/...
⏱️ Live Feed: #Neuroendocrine Control of Cancer #Immunosurveillance, featuring Guido Kroemer.
Spotlight on #ACBP / #DBI, a newly identified #gerogene / #geroprotein with age-dependent expression
Spotlight on #ACBP / #DBI, a newly identified #gerogene / #geroprotein with age-dependent expression
September 17, 2025 at 1:37 PM
⏱️ Live Feed: #Neuroendocrine Control of Cancer #Immunosurveillance, featuring Guido Kroemer.
Spotlight on #ACBP / #DBI, a newly identified #gerogene / #geroprotein with age-dependent expression
Spotlight on #ACBP / #DBI, a newly identified #gerogene / #geroprotein with age-dependent expression
🦠"Diagnosis of gut dysbiosis and relevance for clinical outcome" from Dr Lisa Derosa (Gustave Roussy, France). Key highlights on Linkedin ➡️https://www.linkedin.com/feed/update/urn:li:activity:7374072113168801792
September 17, 2025 at 1:33 PM
🦠"Diagnosis of gut dysbiosis and relevance for clinical outcome" from Dr Lisa Derosa (Gustave Roussy, France). Key highlights on Linkedin ➡️https://www.linkedin.com/feed/update/urn:li:activity:7374072113168801792
🔬 Reprogramming the TME to Overcome Radioresistance Key takeaways from Pr. Tim Illidge (Manchester Cancer Research Centre) at #ImmunoRad2025
--> www.linkedin.com/feed/update/...
--> www.linkedin.com/feed/update/...
September 17, 2025 at 12:51 PM
🔬 Reprogramming the TME to Overcome Radioresistance Key takeaways from Pr. Tim Illidge (Manchester Cancer Research Centre) at #ImmunoRad2025
--> www.linkedin.com/feed/update/...
--> www.linkedin.com/feed/update/...
⏱️ Live Feed: Groundbreaking keynote lecture by Pr Ralph Weichselbaum (University of Chicago, USA)
➡️ www.linkedin.com/posts/immuno...
➡️ www.linkedin.com/posts/immuno...
September 17, 2025 at 10:25 AM
⏱️ Live Feed: Groundbreaking keynote lecture by Pr Ralph Weichselbaum (University of Chicago, USA)
➡️ www.linkedin.com/posts/immuno...
➡️ www.linkedin.com/posts/immuno...
#ImmunoRad2025 kicks off today! 🧬💡
From Sept 17–19 at Cordeliers (Paris), top Key Opinion Leaders and researchers unpack the future of immuno-radiotherapy.
🔴 Follow our live scientific recaps from François de Kermenguy, Paul Bergeron and Nathan Benzazon — don’t miss the latest from the field!
From Sept 17–19 at Cordeliers (Paris), top Key Opinion Leaders and researchers unpack the future of immuno-radiotherapy.
🔴 Follow our live scientific recaps from François de Kermenguy, Paul Bergeron and Nathan Benzazon — don’t miss the latest from the field!
September 17, 2025 at 10:23 AM
#ImmunoRad2025 kicks off today! 🧬💡
From Sept 17–19 at Cordeliers (Paris), top Key Opinion Leaders and researchers unpack the future of immuno-radiotherapy.
🔴 Follow our live scientific recaps from François de Kermenguy, Paul Bergeron and Nathan Benzazon — don’t miss the latest from the field!
From Sept 17–19 at Cordeliers (Paris), top Key Opinion Leaders and researchers unpack the future of immuno-radiotherapy.
🔴 Follow our live scientific recaps from François de Kermenguy, Paul Bergeron and Nathan Benzazon — don’t miss the latest from the field!